摘要
儿童慢性乙型肝炎(CHB)在免疫活动期应开始抗病毒治疗。抗病毒治疗的药物有干扰素(IFN)与核苷和核苷酸类药物(NAs)两大类。概述了儿童CHB抗病毒治疗现状,指出儿童抗病毒治疗首选IFN,但需注意个体化治疗和不良反应的处理;对不能使用干扰素的儿童可以选用有限的NAs,但停药会有复发的高风险,而且一旦产生HBV耐药则会影响后继治疗。未来针对提高抗病毒的疗效、减少不良反应、减少耐药等问题仍需进一步探究。
For children with chronic hepatitis B( CHB),the antiviral therapy should be started in the immune active phase. There are two categories of antiviral drugs used for CHB: interferons( IFNs) and nucleos( t) ide analogues( NAs). In this paper,the current status of antiviral therapy of CHB in children is reviewed. It is pointed out that IFNs are the drug of first choice in antiviral therapy for children with CHB,and the individualized treatment and management of adverse events need to be considered. Some NAs can be given to those special children who cannot accept IFNs. However,there is a high risk of relapse after drug withdrawal. And the subsequent treatment will be seriously affected once the drug resistance is developed. It needs further investigation to improve the efficacy of antiviral therapy and reduce the adverse events and the drug resistance in the future.
出处
《临床肝胆病杂志》
CAS
2015年第8期1211-1214,共4页
Journal of Clinical Hepatology
关键词
肝炎
乙型
慢性
儿童
治疗
hepatitis B
chronic
child
therapy